Adam Keeney
Corporate Officer/Principal bij BIOGEN INC.
Vermogen: 142 747 $ op 31-03-2024
Profiel
Adam Keeney is currently the Executive VP & Head-Corporate Development at Biogen, Inc. Prior to this, he worked as the President, Chief Executive Officer & Director at NodThera Ltd.
He completed his undergraduate degree at the University of Leeds and his doctorate at The University of Nottingham.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
BIOGEN INC.
0.00% | 01-05-2024 | 662 ( 0.00% ) | 142 747 $ | 31-03-2024 |
Actieve functies van Adam Keeney
| Bedrijven | Functie | Begin |
|---|---|---|
| BIOGEN INC. | Corporate Officer/Principal | 17-04-2023 |
Eerdere bekende functies van Adam Keeney
| Bedrijven | Functie | Einde |
|---|---|---|
NodThera Ltd.
 NodThera Ltd. BiotechnologyHealth Technology NodThera Ltd. researches and develops novel inhibitors of the NLRP3 inflammasome. The company is headquartered in Little Chesterford, the United Kingdom. | Chief Executive Officer | - |
Opleiding van Adam Keeney
| University of Leeds | Undergraduate Degree |
| The University of Nottingham | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| BIOGEN INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
NodThera Ltd.
NodThera Ltd. BiotechnologyHealth Technology NodThera Ltd. researches and develops novel inhibitors of the NLRP3 inflammasome. The company is headquartered in Little Chesterford, the United Kingdom. | Health Technology |
